98242-77-4 Purity
99%+
If you have any other questions or need other size, please get a quote.
Specification
Wilde L, et al. International Journal of Pharmaceutics, 2014, 461(1-2), 296-300.
This study reports the design and experimental application of glyceryl tristearate (GTS) capsules as a fasted-stomach, pressure-sensitive dosage form. GTS was melted at 90 °C and cast into hard gelatin capsule molds, which were rotated to ensure uniform solidification. The capsules were then loaded with a 5% hydroxyethyl cellulose hydrogel containing 1.33% paracetamol and sealed with 85 µL of molten GTS. To evaluate mechanical performance, the gelatin coat was dissolved in warm water, preserving the brittle GTS shell for texture analysis. The controlled shell thickness enabled precise modulation of crushing pressure, mimicking pyloric forces. This methodology allowed rapid release of the liquid hydrogel upon mechanical stress, ensuring immediate bioavailability of the active pharmaceutical ingredient in the upper small intestine. The study highlights GTS capsules' practical utility in pressure-triggered oral drug delivery systems.
Gaspar DP, et al. International Journal of Pharmaceutics, 2016, 497(1-2), 199-209.
This study investigates the use of glyceryl tristearate as a lipid matrix in the preparation of rifabutin-loaded solid lipid nanoparticles (SLNs) for pulmonary drug delivery. SLNs were synthesized via a modified hot high-shear homogenization method. The lipid phase, comprising glyceryl tristearate, was melted 10 °C above its melting point, and rifabutin was dissolved within. Simultaneously, an aqueous phase containing Tween 80 was heated to the same temperature and added to the lipid phase under high-shear mixing at 12,300 rpm for 10 minutes. The resulting hot nanoemulsion was cooled in an ice bath with gentle agitation, yielding uniform SLN dispersions. This experimental approach demonstrates the applicability of glyceryl tristearate in producing inhalable nanoparticles with potential for controlled rifabutin release, emphasizing reproducible formulation techniques and precise thermal control during SLN preparation.
Gaspar DP, et al. International Journal of Pharmaceutics, 2017, 516(1-2), 231-246.
This study reports the development of glyceryl tristearate solid lipid nanoparticles (SLNs) as carriers for pulmonary protein delivery. A model protein, papain (PAP), was adsorbed onto SLNs composed of glyceryl tristearate and glyceryl dibehenate. Nanoparticles were prepared via hot high-shear homogenization (HSH), where the lipid phase was melted 10 °C above its melting point and emulsified with an aqueous phase containing Tween® 80. Homogenization was performed at 12,300 rpm for 10 min, followed by controlled cooling in an ice bath with gentle agitation for 5 min. All formulations were prepared in triplicate and stored at 5 ± 3 °C. This methodology ensured reproducible formation of hybrid microencapsulated SLNs, demonstrating the experimental feasibility of glyceryl tristearate SLNs as a versatile platform for protein encapsulation and pulmonary administration.
The molecular formula is C57H110O6.
Another name is TRISTEARIN.
The molecular weight is 891.5 g/mol.
It is found in Lysiphlebia japonica, Sciadopitys verticillata, and other organisms.
The IUPAC Name is 2,3-di(octadecanoyloxy)propyl octadecanoate.
The InChIKey is DCXXMTOCNZCJGO-UHFFFAOYSA-N.
It has 6 hydrogen bond acceptors.
The Exact Mass is 890.83024122 g/mol.
The UNII is P6OCJ2551R.
The CAS number is 555-43-1.
Reference: [1] JAOCS, Journal of the American Oil Chemists' Society, 2000, vol. 77, # 11, p. 1139 - 1145
Reference: [1] Journal of the American Oil Chemists' Society, 1958, vol. 35, p. 416
[2] Journal of the American Chemical Society, 1938, vol. 60, p. 2604
[3] Journal of the American Chemical Society, 1938, vol. 60, p. 2604
[4] Proceedings of the Royal Society of London, Series A: Mathematical, Physical and Engineering Sciences, 1942, vol. 181, p. 31
Reference: [1] Chemische Berichte, 1903, vol. 36, p. 2767[2] Chem. Zentralbl., 1904, vol. 75, # II, p. 413
Reference: [1]Patent: US2017/297988,2017,A1 .Location in patent: Paragraph 0057; 0058
Reference: [1]Chemische Berichte,1921,vol. 54,p. 297
Reference: [1]Journal of the Chemical Society,1959,p. 760,764
* For details of the synthesis route, please refer to the original source to ensure accuracy.
Please kindly note that our products are for research use only.
Download